HF 2242 – Summary
A. Purpose and intent
- The bill directs the Minnesota Commissioner of Human Services to establish a state-level pharmacy benefits management approach by selecting a state pharmacy benefit manager (SPBM) through a formal procurement process.
- It requires the Commissioner to execute a master contract with the SPBM and to define the program’s authority and eligibility requirements, along with a required reporting obligation to the Legislature.
B. Key provisions
- Procurement and selection
- The Commissioner of Human Services must select a state pharmacy benefit manager via a competitive procurement process.
- Master contract
- The Commissioner must enter into a master contract with the SPBM that governs program operations, performance expectations, and other terms.
- Program scope and eligibility
- The bill specifies that program authority and eligibility requirements for participation or enrollment under the SPBM framework will be established (details not provided in the summary).
- Reporting
- The SPBM program (or the Commissioner) is required to prepare and submit a report outlining implementation status, performance metrics, and outcomes to the Legislature.
C. Affected entities
- Primary: Minnesota Department of Human Services (DHS) and its programs that administer or influence prescription drug benefits.
- SPBM, participating health plans or DHS contractors, and participating pharmacies.
- Beneficiaries and providers within DHS-administered programs who would be impacted by a centralized SPBM approach.
D. Procedural and timeline aspects
- Introduction: March 12, 2025.
- Legislative actions (illustrative progress):
- 2025-04-03: Author added Bahner (status update).
- 2025-04-01 and 2025-03-xx: Multiple authors added (indicating growing sponsorship).
- 2025-03-12: Introduction and first reading; referred to Health Finance and Policy.
- Related bill: SF 1574 (companion in the Senate), indicating cross-chamber consideration.
E. Legislative status and related notes
- Current status reflects early-stage sponsorship with multiple authors added since introduction; as of the latest update, Bahner is listed as the author.
- Companion bill SF 1574 suggests parallel consideration in the Senate.
F. Potential impact and considerations (high-level)
- aims to centralize and standardize prescription drug benefits administration under a state-level entity, potentially improving negotiation leverage, consistency of benefits, and oversight.
- Could affect contract terms, reimbursement rates, formulary management, and beneficiary access timelines.
- Implementation would require robust governance, data sharing, and transparency in reporting to monitor savings, access, and beneficiary protections.
G. Related information
- For cross-reference, the companion Senate bill SF 1574 exists.
- This summary reflects publicly available bill information up to the latest actions listed (through early April 2025).
